| Gina Anne Uguccioni, CRNA | |
|
11234 Anderson St, Loma Linda, CA 92354-2804 | |
| (909) 558-4370 | |
| Not Available |
| Full Name | Gina Anne Uguccioni |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 7 Years |
| Location | 11234 Anderson St, Loma Linda, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114457116 | NPI | - | NPPES |
| 95000732 | Other | CA | CRNA |
| 95058239 | Other | CA | RN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 95000732 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Loma Linda University Medical Center | Loma linda, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Faculty Physicians And Surgeons Of Llusm | 1153227814 | 1053 |
News Archive
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
One of the ultimate ways of understanding what impact any particular gene has in human health or disease is to disrupt it-knocking it down or wiping it out in a worm, fly or mouse and gauging what happens next. Now scientists at the University of California, San Francisco (UCSF) Diabetes Center and the Gladstone Institute for Cardiovascular Disease have assembled a large publicly available resource to help researchers determine the importance of genes in mice and better gauge what roles they might play in disease.
Synthesizing useful new compounds is what pharmaceutical discovery and development is all about. Researchers at the School of Science at Indiana University-Purdue University Indianapolis have devised a method to substantially speed up the process.
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has completed the acquisition of Chamberlin Edmonds & Associates, Inc., a leading provider of government program eligibility and enrollment services to over 200 acute care facilities in 31 states. Chamberlin Edmonds' technology-enabled services assist hospitals in lowering the incidence of uncompensated care, reducing bad-debt expense and increasing overall cash flow.
› Verified 9 days ago
| Entity Name | Faculty Physicians And Surgeons Of Llusm |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205009917 PECOS PAC ID: 1153227814 Enrollment ID: O20031211000981 |
News Archive
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
One of the ultimate ways of understanding what impact any particular gene has in human health or disease is to disrupt it-knocking it down or wiping it out in a worm, fly or mouse and gauging what happens next. Now scientists at the University of California, San Francisco (UCSF) Diabetes Center and the Gladstone Institute for Cardiovascular Disease have assembled a large publicly available resource to help researchers determine the importance of genes in mice and better gauge what roles they might play in disease.
Synthesizing useful new compounds is what pharmaceutical discovery and development is all about. Researchers at the School of Science at Indiana University-Purdue University Indianapolis have devised a method to substantially speed up the process.
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has completed the acquisition of Chamberlin Edmonds & Associates, Inc., a leading provider of government program eligibility and enrollment services to over 200 acute care facilities in 31 states. Chamberlin Edmonds' technology-enabled services assist hospitals in lowering the incidence of uncompensated care, reducing bad-debt expense and increasing overall cash flow.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gina Anne Uguccioni, CRNA 1400 Barton Rd Apt 911, Redlands, CA 92373-5493 Ph: (413) 774-0588 | Gina Anne Uguccioni, CRNA 11234 Anderson St, Loma Linda, CA 92354-2804 Ph: (909) 558-4370 |
News Archive
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
One of the ultimate ways of understanding what impact any particular gene has in human health or disease is to disrupt it-knocking it down or wiping it out in a worm, fly or mouse and gauging what happens next. Now scientists at the University of California, San Francisco (UCSF) Diabetes Center and the Gladstone Institute for Cardiovascular Disease have assembled a large publicly available resource to help researchers determine the importance of genes in mice and better gauge what roles they might play in disease.
Synthesizing useful new compounds is what pharmaceutical discovery and development is all about. Researchers at the School of Science at Indiana University-Purdue University Indianapolis have devised a method to substantially speed up the process.
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has completed the acquisition of Chamberlin Edmonds & Associates, Inc., a leading provider of government program eligibility and enrollment services to over 200 acute care facilities in 31 states. Chamberlin Edmonds' technology-enabled services assist hospitals in lowering the incidence of uncompensated care, reducing bad-debt expense and increasing overall cash flow.
› Verified 9 days ago
Joseph M Wilkinson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 11234 Anderson St, Loma Linda, CA 92354 Phone: 909-558-4475 | |
Kurt Dieter Cao, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 11234 Anderson St, Loma Linda, CA 92354 Phone: 909-558-8173 | |
Edwin E Dupper, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 11234 Anderson St, Loma Linda, CA 92354 Phone: 909-558-4475 | |
Mr. Jose Kadry Ii, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 11234 Anderson St, Loma Linda, CA 92354 Phone: 909-558-7811 Fax: 909-558-4143 | |
Rochelle Antoinette Solorzano, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 11234 Anderson St, Loma Linda, CA 92354 Phone: 909-558-7811 | |
Karin Zabel Nercissian, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 11201 Benton St, Loma Linda, CA 92357 Phone: 909-825-7084 | |
Bituin Oben, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 11234 Anderson St, Loma Linda, CA 92354 Phone: 909-558-7811 |